Unlock instant, AI-driven research and patent intelligence for your innovation.

Identification, Optimization And Use Of Cryptic HLA-B7 Epitopes For Immunotherapy

a technology of hla-b7 and cryptic hlab7, which is applied in the field of peptide immunotherapy, can solve the problems of insufficient mhc i affinity, presence of primary anchor residues, and often necessary, and achieve the effect of enhancing affinity and immunogenicity of hla-b

Inactive Publication Date: 2013-10-10
KOSMATOPOULOS KOSTANTINOS +2
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method to improve the immunogenicity of a certain peptide that is restricted by a specific allele of the human leukocyte antigen B* 0702. By substituting the N-terminal or C-terminal residue of the peptide with a specific amino acid, such as alanine or leucine, its immunogenicity can be increased. This method can be utilized in the development of a vaccination protocol to target cryptic epitopes and maintain the immune response initiated by a native peptide.

Problems solved by technology

The presence of primary anchor residues although often necessary is not sufficient to ensure a high MHC I affinity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Identification, Optimization And Use Of Cryptic HLA-B7 Epitopes For Immunotherapy
  • Identification, Optimization And Use Of Cryptic HLA-B7 Epitopes For Immunotherapy
  • Identification, Optimization And Use Of Cryptic HLA-B7 Epitopes For Immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Affinity of Peptides

[0075]Eight peptides with the HLA-B*0702 specific anchor motifs, i.e. P2 and preferentially L / V at C-terminal position (Sidney et al., 1996) belonging to Hsp70 (Hsp70115, Hsp70137, Hsp70397), TERT (TERT4 and TERT444), and MAGE-A (MAGE-A121.1, MAGE-A121.2 and MAGE-A121.4) antigens were tested for binding to the HLA-B*0702 molecule. Only TERT4 bound to HLA-B*0702 with a high affinity, the remaining seven peptides were very weak or non binders (Table II). This demonstrates that the presence of anchor motifs is not sufficient to ensure a high binding affinity to HLA-B*0702. Given their low affinity, peptides Hsp70115, Hsp70137, Hsp70397, TERT444, MAGE-A121.1, MAGE-A121.2, MAGE-A121.4, are considered cryptic peptides.

TABLE IIHLA-B*0702 affinity of peptidesSEQ IDPeptideSequenceRANO:1Hsp70 115YPEEISSMVL>1011Hsp70 115A1APEEISSMVL>10122Hsp70 137 (10)YPVTNAVITV>10133Hsp70 397APLSLGLET>10144TERT4APRCRAVRSL  0.74155TERT444DPRRLVQLL>101TERT 444A1APRRLVQLL  1.456MAGE-A121.1EPV...

example 2

Immunogenicity of Selected Peptides

[0076]The low affinity Hsp137, Hsp115, Hsp397, TERT444 and the high affinity TERT4 peptides have been tested for their capacity to induce a specific CTL immune response in HLA-B*0702 transgenic mice. Only the high affinity TERT4 was immunogenic confirming that immunogenicity of peptides is strongly related to their affinity for HLA (FIG. 1).

example 3

Enhancement of Affinity of Low Affinity Peptides

[0077]Since all these cryptic peptides had favourable primary anchor motifs, enhancement of their affinity is a prerequisite for them to be immunogenic. It required the identification of unfavourable secondary anchor motifs and their substitution with favourable motifs. These substitutions should however preserve the conformation of the peptide segment that interacts with the TCR (position 4 to position 8). The interest was, therefore, focused on secondary anchor positions 1 and 3: aliphatic amino acids are favourable motifs at position 1 (Sidney, Southwood et al., 1996). However, peptides Hsp70115 and Hsp70137 that have a Y (tyrosine) at position 1 are non binders. Moreover, the substitution of the amino acid at position 1 by an A (alanine) that is also favourable at this position. (Parker et al, 1994) enhances the affinity of the TERT444 but not of the Hsp70115 and the MAGE-A121.1 peptides (Table II). This indicates that the presence...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
MHC I affinityaaaaaaaaaa
binding affinityaaaaaaaaaa
Login to View More

Abstract

The invention provides methods for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, as well as methods for increasing the immunogenicity of HLA-B*0702-restricted cryptic epitopes. The HLA-B*0702-restricted cryptic epitopes and their cognate immunogenic epitopes are useful for stimulating an immune reaction against the cryptic epitopes in a subject. Accordingly, the invention further provides pharmaceutical compositions comprising a HLA-B*0702-restricted cryptic epitope or a cognate immunogenic epitope thereof, and vaccination kits comprising such epitopes. The novel materials of the invention are particularly useful for efficiently treating patients having an HLA-B*0702 phenotype.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. application Ser. No. 12 / 373,408, filed Jul. 9, 2009, which is a national stage application filed under 35 U.S.C. 371 of International Application No. PCT / IB2007 / 003054, filed Jul. 12, 2007, which claims priority from International Application No. PCT / IB2006 / 002937, filed Jul. 12, 2006, each of which is incorporated herein by reference in its entirety.REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING SUBMITTED IN COMPUTER READABLE FORMAT[0002]The Sequence Listing written in the file 433674SEQLIST.txt is 14,722 bytes, and was created on Jun. 14, 2013, for the application filed herewith, Kosmatopoulos et al. “Identification, Optimization and Use of Cryptic HLA-B7 Epitopes for Immunotherapy.” The information contained in this file is hereby incorporated by reference.FIELD AND BACKGROUND OF THE INVENTION[0003]The present invention relates to the field of peptide immunotherapy. In...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/74A61K39/00
CPCA61K38/00A61K39/00A61K39/0011C07K7/06C07K14/005C07K14/70539C12N2740/16122C12N2740/16222C12N2740/16322A61K39/0005C07K14/4748A61P31/12A61P35/00A61P37/04A61P43/00A61K39/4611A61K39/464457C07K7/04A61K38/04A61K2039/54A61K2039/545A61K2039/572
Inventor KOSMATOPOULOS, KOSTANTINOSGRAFF-DUBOIS, STEPHANIEMENEZ-JAMET, JEANNE
Owner KOSMATOPOULOS KOSTANTINOS